NCT05163028View on ClinicalTrials.gov

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Non Small Cell Lung CancerColorectal CancerPancreatic CancerSolid TumorCancerCancer of PancreasCancer of Colon
Interventions
DRUG

HBI-2376

SHP2 Inhibitor

Trial Locations (12)

22031

Virginia Cancer Specialists, Fairfax

32806

Orlando Health, Inc., Orlando

33322

BRCR Medical Center, Plantation

44718

Gabrail Cancer Center, Canton

75702

Texas Oncology - Tyler, Tyler

90403

Sarcoma Oncology, Santa Monica

90404

UCLA Hematology/Oncology, Santa Monica

91010

City of Hope, Duarte

92024

California Cancer Associates for Research and Excellence, Inc. (cCare), Encinitas

92069

California Cancer Associates for Research and Excellence, Inc. (cCare), San Marcos

92835

Providence Medical Foundation, Fullerton

00935

Pan American Center for Oncology Trials (PanOncology Trials), Rio Piedras

All Listed Sponsors
lead

HUYABIO International, LLC.

INDUSTRY